Fig. 2.

HDV kinetic patterns under BLV monotherapy in patients with compensated cirrhosis and clinically significant portal hypertension.

(A) Monophasic, i.e. a single phase of viral decline (n = 2), (B) biphasic, viral decline consisting of a first phase decline that was 2-fold faster than the second phase decline (n = 8), (C) FPR, defined as a first phase viral decline followed by a plateau that was not significantly (p >0.05) different from slope=0 (n = 3), (D) FPR followed by decline (n = 1), (E) Biphasic followed by breakthrough (n = 2), and (F) non-responder, defined as having <∼1.0 log IU/ml decline from baseline (n = 2). Solid lines for HDV reflect modelling using piecewise linear regression and dashed lines between ALT markers are shown only to highlight the trajectory. ALT, alanine aminotransferase; BLV, bulevirtide; FPR, flat-partial response; HDV, hepatitis D virus.